Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JK		6221633		ERTL	04-24-2001	
JK		6221897		BARINGHAUS	04-24-2001	
JK		6245744		BARINGHAUS	06-12-2001	
JK		6342512		KIRSCH	01-29-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JK	✓	EP	0 193 249		Duphar International Research	09-03-1986		
JK	✓	EP	0 462 884		Adir Et Compagnie	12-27-1991		
JK	✓	DE	10142734		GLOMBIK	03-27-2003		
JK	✓	DE	DE 694 05 815		Zeneca Ltd.	02-05-1998		
JK	✓	WO	00/64876		Aventis Pharmaceuticals Prodi	11-02-2000		
JK	✓	WO	00/64888		Aventis Pharmaceuticals Prodi	11-02-2000		
JK		WO	01/94300		DEFOSSA	12-13-2001		
JK		WO	WO 00/40569		Alizyme Therapeutics Limited	07-13-2000		
JK		WO	WO 00/63208		Novo Nordisk A/S	10-26-2000		
JK		WO	WO 00/66585		Neurogen Corporation	11-09-2000		

Examiner Signature		Date Considered	06-20-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complet if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
[illegible]		WO	WO 00/71549		Knoll Aktiengesellschaft	11-30-2000		
[illegible]		WO	WO 00/78312		Merck & Co., Inc.	12-28-2000		
[illegible]		WO	WO 01/09111		Eli Lilly And Company	02-08-2001		
[illegible]		WO	WO 01/83451		Asahi Kasei Kabushiki Kaisha	11-08-2001		
[illegible]		WO	WO 01/85695		Bristol-Myers Squibb Co.	11-15-2001		
[illegible]		WO	WO 97/26265		Novo Nordisk A/S	07-24-1997		
[illegible]		WO	WO 97/41097		Dr. Reddy's Research Foundat	11-06-1997		
[illegible]		WO	WO 98/08871		Novo Nordisk A/S	03-05-1998		
[illegible]		WO	WO 99/03861		Novo Nordisk A/S	01-28-1999		
[illegible]		WO	WO 99/15525		Sanofi	04-01-1999		

Examiner Signature	[signature]	Date Considered	06-20-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Compl te if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
NA		ASAKAWA A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety And Gastric Emptying In Mice, Horm Metab Res, (2001), Vol. 33, pp. 554 - 558	
NA		LEE Daniel W. et al., Leptin Agonists As A Potential Approach To The Treatment Of Obesity, Drugs Of The Future, (2001), Vol. 26, No. 9, pp. 873 - 881	
NA		OKADA Hiroshi et al., Synthesis And Antitumor Activities Of Prodrugs Of Benzoylphnylureas, Chem. Pharm. Bull., (1994), Vol. 42, No. 1, pp. 57 - 61	
NA		ROUSSET Monique et al., Growth-Related Glycogen Levels Of Human Intestine Carcinoma Cell Lines Grown In Vitro And In Vivo In Nude Mice, JNCI, (1980), Vol. 65, No. 5, pp. 885 - 889	
NA		SALVADOR Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opin. Pharmacother., (2001), Vol. 2, No. 10, pp. 1615 - 1622	
NA		SKWARSKI L. et al., Glycogen Content In The Gastric Mucosa Of Partially Resected Stomach; A Possible Relationship With The Development Of Cancer, Cancer Letters, (1998), Vol. 127, pp. 123 - 128	
NA		TAKAHASHI Shigeki et al., Estimation Of Glycogen Levels In Human Colorectal Cancer Tissue: Relationship With Cell Cycle And Tumor Outgrowth, J. Gastroenterol, (1999), Vol. 34, pp. 474 - 480	
NA		TREADWAY Judith L. et al., Glycogen Phosphorylase Inhibitors For Treatment Of Type 2 Diabetes Mellitus, Exp. Opin. Invest. Drugs, (2001), Vol. 10, No. 3, pp. 439 - 454	
NA		TYLE Praveen, Iontophoretic Devices For Drug Delivery, Pharmaceutical Research, (1986), Vol. 3, No. 6, pp. 318 - 326	
NA		YANO Kazuyuki et al., Evaluation Of Glycogen Level In Human Lung Carcinoma Tissues By An Infrared Spectroscopic Method , Cancer Letters, (1996), Vol. 110, pp. 29 - 34	

Examiner Signature		Date Considered	06-20-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
NR		ZUNFIT H. J. F. et al., Carob Pulp Preparation For Treatment Of Hypercholesterolemia, Advances In Therapy, (2001), Vol. 18, No. 5, pp. 231 - 236	

Examiner Signature		Date Considered	06-20-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.